NovaBay Pharmaceuticals, Inc. (AMEX:NBY) biopharmaceutical firm, is expected to report third quarter earnings results, after market close, on Thursday 12th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.04 per share.
Looking ahead, the full year loss are expected at $ 0.25 per share on the revenues of $ 11.36 million.
Previous Quarter Performance
NovaBay Pharmaceuticals, Inc. reported loss for the second quarter of $ 0.15 per share, from the revenue of $ 3.98 million. The quarterly revenues gained 122.35 percent compared with the same quarter last year. Street analysts expected NovaBay Pharmaceuticals, Inc. to report loss of $ 0.05 per share on revenue of $ 2.85 million for the second quarter. The bottom line results missed street analysts by $ 0.1 or 200 percent, at the same time, top line results outshined analysts by $ 1.13 million or 39.65 percent.
Stock Performance
Shares of NovaBay Pharmaceuticals, Inc. traded up $ 0.04 or 6.16 percent on Wednesday, reaching $ 0.62 with volume of 624.00 thousand shares. NovaBay Pharmaceuticals, Inc. has traded high as $ 0.64 and has cracked $ 0.57 on the downward trend
The closing price of $ 0.62, representing a 141.67 % increase from the 52 week low of $ 0.24 and a 70.1 % decrease over the 52 week high of $ 1.94.
The company has a market capital of $ 27.58 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
NovaBay Pharmaceuticals, Inc. will be hosting a conference call at 4:30 PM eastern time on 12th November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, 866-677-7731 U.S. or 480-405-6745 Toll Number in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.novabay.com
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc.
